Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darapladib in chronic coronary heart disease (STABILITY)
NCT00799903Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2008
- Primary completion
- Oct 2013
- Countries
- 39
01
Overview
Phase 3, randomised, double-blind trial of darapladib in coronary heart disease (CHD) and atherosclerosis, sponsored by GSK. Started Dec 2008; status: completed.
02
Drugs
darapladib
03
Conditions
coronary heart disease (CHD)atherosclerosis
Beyond the preview
Go deeper on NCT00799903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00799903.